drugset / Trial / NCT00760864
Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of TAK-715, twice daily (BID), in the treatment of rheumatoid arthritis signs and symptoms in patients with a partial response to methotrexate.
Timeline
- Start
- 2004-08
- Primary completion
- 2005-09
- Completion
- 2005-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAK-715 | Small molecule | 25 mg | Oral |
| Subject | TAK-715 | Small molecule | 50 mg | Oral |
| Subject | TAK-715 | Small molecule | 100 mg | Oral |
| Background | Methotrexate | Small molecule | — | — |